- Home
- VNDA vs ALDX Comparison
VNDA vs ALDX Comparison
Compare VNDA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- ALDX
- Stock Information
- Founded
- VNDA 2002
- ALDX 2004
- Country
- VNDA United States
- ALDX United States
- Employees
- VNDA N/A
- ALDX N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- ALDX Health Care
- Exchange
- VNDA Nasdaq
- ALDX Nasdaq
- Market Cap
- VNDA 270.2M
- ALDX 319.4M
- IPO Year
- VNDA 2006
- ALDX 2014
- Fundamental
- Price
- VNDA $4.94
- ALDX $4.81
- Analyst Decision
- VNDA Strong Buy
- ALDX Strong Buy
- Analyst Count
- VNDA 2
- ALDX 2
- Target Price
- VNDA $15.50
- ALDX $10.00
- AVG Volume (30 Days)
- VNDA 643.5K
- ALDX 544.4K
- Earning Date
- VNDA 11-06-2024
- ALDX 11-07-2024
- Dividend Yield
- VNDA N/A
- ALDX N/A
- EPS Growth
- VNDA N/A
- ALDX N/A
- EPS
- VNDA N/A
- ALDX N/A
- Revenue
- VNDA $190,858,000.00
- ALDX N/A
- Revenue This Year
- VNDA $5.13
- ALDX N/A
- Revenue Next Year
- VNDA $42.65
- ALDX $25.36
- P/E Ratio
- VNDA N/A
- ALDX N/A
- Revenue Growth
- VNDA N/A
- ALDX N/A
- 52 Week Low
- VNDA $3.46
- ALDX $2.43
- 52 Week High
- VNDA $6.75
- ALDX $6.55
- Technical
- Relative Strength Index (RSI)
- VNDA 50.36
- ALDX 44.70
- Support Level
- VNDA $4.82
- ALDX $4.09
- Resistance Level
- VNDA $5.55
- ALDX $5.01
- Average True Range (ATR)
- VNDA 0.22
- ALDX 0.40
- MACD
- VNDA -0.02
- ALDX -0.03
- Stochastic Oscillator
- VNDA 32.22
- ALDX 43.64
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.